Advanced search
Publication Cover
Immunological Medicine Volume 42, 2019 - Issue 2
Submit an article Journal homepage
3,740
Views
0
CrossRef citations to date
0
Altmetric
Case Report

A case of psoriatic arthritis, with joint involvement preceding skin involvement, successfully treated with adalimumab (80 mg every other week)

Yuki NankeInstitute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan; Correspondence[email protected]
,
Tsuyoshi KobashigawaSaitama Medical Center, Jichi Medical University, Saitama, Japan
,
Naoki SugimotoInstitute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan;
,
Hisashi YamanakaInstitute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan;
&
Shigeru KotakeSaitama Medical Center, Jichi Medical University, Saitama, Japan
Pages 99-102 | Received 05 May 2019, Accepted 11 Aug 2019, Published online: 25 Aug 2019

References

  • Gottlieb AB, Mease PJ, Jackson M, et al. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists’s offices. J Derma Treat. 2006;17:279–287.
  • Lenert P, Jovanovic M, Mitic I, et al. Psoriatic arthritis: case report of acute HLA-B27 positive polyarthritis preceding the onset of typical skin changes. Med Pregl. 1997;50:387–390.
  • Yeremenko N, Paramarta JE, Baeten D. The interleukin-23/interleukin-17 immune axis as a promising new target in the treatment of spondyloarthritis. Curr Opin Rheumatol. 2014;26:361–371.
  • Ritchlin C, Haas-Smith SA, Hicks D, et al. Pattern of cytokine production in psoriatic synovium. J Rheumatol. 1998;25:1544–1552.
  • Douglas JV, Ursula F. The pathogenesis of psoriatic arthritis. Lancet. 2018;391:2273–2284.
  • Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest. 2003;111:821–831.
  • Stuart PE, Nair RP, Tsoi LG, et al. Genome-wide association anaylysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture. Am J Hum Genet. 2015;97:816–836.
  • Haroon M, Winchester R, Giles JT, et al. Certain class of HLA alleles and haplotypes implicated in susceptibility play a role in determining specific features of the psoriatic arthritis phenotype. Ann Rheum Dis. 2016;75:155–162.
  • Asahina A, Ohtsuki M, Etoh T, et al. Adalimumab treatment optimization for psoriasis: results of a long-term phase 2/3 Japanese study. J Derma Treat. 2015;42:1–11.
  • Asahina A, Torii H, Ohtsuki M, et al. Safety and efficacy of adalimumab treatment in Japanese patients with psoriasis: results of SALSA study. J Dermatol. 2016;43:1257–1266.
  • Asahina A, Nakagawa H, Etoh T, et al. Adalimumab M04-688 Study Group. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis (2013 version). Dermatological Association. J Dermatol. 2013;40:683–695.
  • Leonardi C, Sobell JM, Crowley JJ, et al. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results form an open –label study. Br J Dermatol. 2012;167:658–667.
  • Lubrabo E, Massimo Perrotta F, Manara M, et al. Predictors of loss of remission and disease flares in patients with axial spondyloarthritis receiving antitumor necrosis factore treatment: a retrospective study. J Rheumatol. 2016;43:1541–1546.
  • Weitz JE, Ritchlin CT. Ustekinumab: targeting the IL-17 pathway to improve outcomes in psoriatic arthritis. Expert Opin Biol Ther. 2014;14:515–526.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.